Samsung Bioepis Posts 6% Growth in First-Half Sales and Operating Profit ... "Strengthening Global Biosimilar Expansion"
First-Half Sales Reach 847.1 Billion Won, Operating Profit at 230.6 Billion Won
Driven by Expanded Direct Sales in Europe and Accelerated US Market Growth
Keytruda Biosimilar Demonstrates Equivalence in Phase 3 Clinical Trial
Samsung Bioepis maintained robust growth during the first half of this year, recording sales of 847.1 billion won and operating profit of 230.6 billion won. The company's results were supported by business expansion in major markets, including increased direct sales of biosimilar products in Europe and the full-scale launch of sales in the US market.
On July 24, Samsung Bioepis announced through its holding company Samsung Epis Holdings’ earnings report that first-half sales reached 847.1 billion won, up 6% (45.5 billion won) year-on-year, while operating profit amounted to 230.6 billion won, a 6% (12.8 billion won) increase over the same period last year.
Looking solely at the second quarter, sales stood at 392.2 billion won and operating profit at 86.6 billion won, which represents a 2% (8.8 billion won) decrease in sales and a 4% (3.2 billion won) decrease in operating profit compared to the same period last year. The company attributed these declines to changes in the supply schedule of key products as well as increased investments in research and development (R&D). However, Samsung Bioepis expects its growth trend to continue into the second half of the year, as the increased demand in core markets such as Europe and the US is gradually reflected in its results.
The upward earnings trajectory has been driven by rising demand for the company’s products in major markets, including Europe and the US. In Europe, the company increased its directly sold products to five types by launching an Aflibercept (Eylea) biosimilar this past May, and in the US, it began full-scale sales of a Denosumab (Prolia) biosimilar. Furthermore, the company expanded its global reach by launching its first product, a Ustekinumab (Stelara) biosimilar, in the Japanese market in May.
The company also delivered results in its research and development pipeline. Last month, it released Phase 1 and Phase 3 clinical trial results for its Pembrolizumab (Keytruda) biosimilar “SB27,” demonstrating equivalence in the primary endpoints of pharmacokinetics (PK) and efficacy to the original drug. Samsung Bioepis is the first in the industry to announce global Phase 3 clinical trial results for a Keytruda biosimilar, a fiercely competitive field. Additionally, its antibody-drug conjugate (ADC) candidate “SBE303” entered global Phase 1 trials for solid tumor patients in March, and its second ADC candidate, “SBE313,” is currently in the preclinical stage. The company is also accelerating the development of long-acting obesity treatments and is pursuing new drug development in various fields based on open innovation.
The holding company, Samsung Epis Holdings, reported consolidated first-half sales of 845.8 billion won and operating profit of 149.3 billion won, taking into account non-cash accounting adjustments. For the second quarter, sales were 391.9 billion won and operating profit was 58.8 billion won. Based on the strong results of its core subsidiary Samsung Bioepis, Samsung Epis Holdings is building out a business structure under the holding company model, and last month, it established its first overseas R&D base in China.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, despite uncertainties in the global market, Samsung Epis Holdings maintained its annual sales growth forecast for its key subsidiary, Samsung Bioepis, at over 10% compared to last year’s 1.672 trillion won.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.